132 related articles for article (PubMed ID: 37442655)
1. Fezolinetant.
Beninger P
Clin Ther; 2023 Aug; 45(8):802-803. PubMed ID: 37442655
[No Abstract] [Full Text] [Related]
2. Fezolinetant.
Am J Health Syst Pharm; 2023 Aug; 80(17):1113-1114. PubMed ID: 37382493
[No Abstract] [Full Text] [Related]
3. Fezolinetant: First Approval.
Lee A
Drugs; 2023 Aug; 83(12):1137-1141. PubMed ID: 37462862
[TBL] [Abstract][Full Text] [Related]
4. Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms.
Pinkerton JV; Redick DL; Homewood LN; Kaunitz AM
J Clin Endocrinol Metab; 2023 Oct; 108(11):e1448-e1449. PubMed ID: 37097747
[No Abstract] [Full Text] [Related]
5. Fezolinetant (Veozah) for menopausal vasomotor symptoms.
Med Lett Drugs Ther; 2023 Jun; 65(1679):97-99. PubMed ID: 37339088
[No Abstract] [Full Text] [Related]
6. Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant.
Douxfils J; Beaudart C; Dogné JM
Lancet; 2023 Nov; 402(10413):1623-1625. PubMed ID: 37865107
[No Abstract] [Full Text] [Related]
7. Fezolinetant (Veozah) for the Treatment of Menopause Symptoms.
Crespo C; Erlich D
Am Fam Physician; 2024 Mar; 109(3):273-274. PubMed ID: 38574221
[No Abstract] [Full Text] [Related]
8. Finding SKYLIGHT for all: fezolinetant efficacy for vasomotor symptoms in subpopulations.
Reed SD
Menopause; 2024 Apr; 31(4):245-246. PubMed ID: 38517209
[No Abstract] [Full Text] [Related]
9. The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council.
Wright AC; Beaudoin FL; McQueen RB; Yeung K; Moradi A; Herron-Smith S; Gutierrez E; Lin GA; Pearson SD
J Manag Care Spec Pharm; 2023 Jun; 29(6):692-698. PubMed ID: 37276043
[No Abstract] [Full Text] [Related]
10. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.
Depypere H; Timmerman D; Donders G; Sieprath P; Ramael S; Combalbert J; Hoveyda HR; Fraser GL
J Clin Endocrinol Metab; 2019 Dec; 104(12):5893-5905. PubMed ID: 31415087
[TBL] [Abstract][Full Text] [Related]
11. Fezolinetant findings can fuel future instrumentation inquiries.
Carpenter JS
Menopause; 2020 Dec; 27(12):1347. PubMed ID: 33048862
[No Abstract] [Full Text] [Related]
12. Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome.
Fraser GL; Obermayer-Pietsch B; Laven J; Griesinger G; Pintiaux A; Timmerman D; Fauser BCJM; Lademacher C; Combalbert J; Hoveyda HR; Ramael S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3519-e3532. PubMed ID: 34000049
[TBL] [Abstract][Full Text] [Related]
13. Totality of evidence refutes neoplasm risk with fezolinetant.
Neal-Perry G; Santoro N; Cano A; Nappi RE; Shapiro M; Ottery FD
Lancet; 2024 May; 403(10440):1987-1988. PubMed ID: 38762322
[No Abstract] [Full Text] [Related]
14. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).
Santoro N; Waldbaum A; Lederman S; Kroll R; Fraser GL; Lademacher C; Skillern L; Young J; Ramael S
Menopause; 2020 Dec; 27(12):1350-1356. PubMed ID: 32769757
[TBL] [Abstract][Full Text] [Related]
15. Totality of evidence refutes neoplasm risk with fezolinetant - Authors' reply.
Douxfils J; Beaudart C; Dogné JM
Lancet; 2024 May; 403(10440):1988. PubMed ID: 38762323
[No Abstract] [Full Text] [Related]
16. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
Fraser GL; Lederman S; Waldbaum A; Kroll R; Santoro N; Lee M; Skillern L; Ramael S
Menopause; 2020 Apr; 27(4):382-392. PubMed ID: 32102086
[TBL] [Abstract][Full Text] [Related]
17. Fezolinetant in the treatment of vasomotor symptoms associated with menopause.
Depypere H; Lademacher C; Siddiqui E; Fraser GL
Expert Opin Investig Drugs; 2021 Jul; 30(7):681-694. PubMed ID: 33724119
[No Abstract] [Full Text] [Related]
18. Scaffold hopping of fused piperidine-type NK3 receptor antagonists to reduce environmental impact.
Yamamoto K; Inuki S; Ohno H; Oishi S
Bioorg Med Chem; 2019 May; 27(10):2019-2026. PubMed ID: 30975505
[TBL] [Abstract][Full Text] [Related]
19. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
Neal-Perry G; Cano A; Lederman S; Nappi RE; Santoro N; Wolfman W; English M; Franklin C; Valluri U; Ottery FD
Obstet Gynecol; 2023 Apr; 141(4):737-747. PubMed ID: 36897180
[TBL] [Abstract][Full Text] [Related]
20. Deal watch: Neurokinin 3 receptor antagonist revival heats up with Astellas acquisition.
Cully M
Nat Rev Drug Discov; 2017 May; 16(6):377. PubMed ID: 28559557
[No Abstract] [Full Text] [Related]
[Next] [New Search]
